Načítá se...
4CPS-038 Initial experience with the use of pcsk9-inhibitors in the real-world clinical practice
BACKGROUND: New lipid-lowering therapies with excellent results on LDL cholesterol (LDL-C) levels came to market at more than five times the cost of the most effective statin regimen. We need strategies to put these treatments into practice and ensure their cost effectiveness. PURPOSE: In December 2...
Uloženo v:
| Vydáno v: | Eur J Hosp Pharm |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BMJ Group
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7535474/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.129 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|